Hosted by the European Association for Cancer Research (EACR)
This conference will delve into the most cutting-edge studies that have revealed novel molecular pathways involved in response to anticancer therapy.
Discover the latest breakthroughs in cancer research; instead of relying on outdated cell line-based preclinical tests, recent studies have taken a bold new approach by testing conventional chemotherapy and hormone therapy directly on in vivo models and patients. These innovative methods have led to the discovery of previously unknown modes of action and cellular effects that have the potential to revolutionize cancer treatment.
Target audience
- Medical and clinical oncologists with interest in translational research, biology and pharmacology
- Basic scientists with interest in translational research and preclinical models
- Colleagues from industry with a focus on molecular pharmacology and drug repositioning
Topics to be covered
- The role of mitochondrial homeostasis in therapy response
- Revisiting molecular pharmacology of historical chemotherapeutic agents: latest and disruptive advances
- Tumour microenvironment
- Experimental therapeutics in model systems